New oral anticoagulants in venous thromboembolism prophylaxis in orthopaedic patients: Are they really better?

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Prophylaxis against venous thromboembolism (VTE) is considered standard of care. Appropriate chemoprophylaxis for VTE has been mandated by the United States government agencies and consumer groups. However, controversies exist regarding the most clinically relevant and safe chemoprophylaxis protocols in patients undergoing joint replacement surgery. Thus, this paper reviews the clinical efficacy and safety of newer oral anticoagulants. A literature search was performed for oral anticoagulants in advanced stages of development using PubMed and abstracts from thrombosis meetings. Most clinical trial data have demonstrated equal or superior efficacy in venographic endpoints in comparison to low-molecular-weight heparins (LMWH). However, bleeding complications have been reported to occur with oral anticoagulants as frequently as or more frequently than with LMWH. Other potential complications reported include liver enzyme elevation and cardiac irregularities. It remains to be established whether newer oral anticoagulants will be better alternatives to the current standard-ofcare in real-life medical clinical practice.

Original languageEnglish (US)
Pages (from-to)45-57
Number of pages13
JournalThrombosis and Haemostasis
Volume106
Issue number1
DOIs
StatePublished - Jul 2011

Fingerprint

Venous Thromboembolism
Anticoagulants
Orthopedics
Low Molecular Weight Heparin
Chemoprevention
United States Government Agencies
Replacement Arthroplasties
Standard of Care
PubMed
Thrombosis
Clinical Trials
Hemorrhage
Safety
Liver
Enzymes

Keywords

  • Oral anticoagulants
  • Prophylaxis
  • Safety
  • Venous thromboembolism

ASJC Scopus subject areas

  • Hematology

Cite this

@article{dceaf08a19044682ac82a9e732ed5984,
title = "New oral anticoagulants in venous thromboembolism prophylaxis in orthopaedic patients: Are they really better?",
abstract = "Prophylaxis against venous thromboembolism (VTE) is considered standard of care. Appropriate chemoprophylaxis for VTE has been mandated by the United States government agencies and consumer groups. However, controversies exist regarding the most clinically relevant and safe chemoprophylaxis protocols in patients undergoing joint replacement surgery. Thus, this paper reviews the clinical efficacy and safety of newer oral anticoagulants. A literature search was performed for oral anticoagulants in advanced stages of development using PubMed and abstracts from thrombosis meetings. Most clinical trial data have demonstrated equal or superior efficacy in venographic endpoints in comparison to low-molecular-weight heparins (LMWH). However, bleeding complications have been reported to occur with oral anticoagulants as frequently as or more frequently than with LMWH. Other potential complications reported include liver enzyme elevation and cardiac irregularities. It remains to be established whether newer oral anticoagulants will be better alternatives to the current standard-ofcare in real-life medical clinical practice.",
keywords = "Oral anticoagulants, Prophylaxis, Safety, Venous thromboembolism",
author = "Huo, {Michael H.}",
year = "2011",
month = "7",
doi = "10.1160/TH10-10-0653",
language = "English (US)",
volume = "106",
pages = "45--57",
journal = "Thrombosis and Haemostasis",
issn = "0340-6245",
publisher = "Schattauer GmbH",
number = "1",

}

TY - JOUR

T1 - New oral anticoagulants in venous thromboembolism prophylaxis in orthopaedic patients

T2 - Are they really better?

AU - Huo, Michael H.

PY - 2011/7

Y1 - 2011/7

N2 - Prophylaxis against venous thromboembolism (VTE) is considered standard of care. Appropriate chemoprophylaxis for VTE has been mandated by the United States government agencies and consumer groups. However, controversies exist regarding the most clinically relevant and safe chemoprophylaxis protocols in patients undergoing joint replacement surgery. Thus, this paper reviews the clinical efficacy and safety of newer oral anticoagulants. A literature search was performed for oral anticoagulants in advanced stages of development using PubMed and abstracts from thrombosis meetings. Most clinical trial data have demonstrated equal or superior efficacy in venographic endpoints in comparison to low-molecular-weight heparins (LMWH). However, bleeding complications have been reported to occur with oral anticoagulants as frequently as or more frequently than with LMWH. Other potential complications reported include liver enzyme elevation and cardiac irregularities. It remains to be established whether newer oral anticoagulants will be better alternatives to the current standard-ofcare in real-life medical clinical practice.

AB - Prophylaxis against venous thromboembolism (VTE) is considered standard of care. Appropriate chemoprophylaxis for VTE has been mandated by the United States government agencies and consumer groups. However, controversies exist regarding the most clinically relevant and safe chemoprophylaxis protocols in patients undergoing joint replacement surgery. Thus, this paper reviews the clinical efficacy and safety of newer oral anticoagulants. A literature search was performed for oral anticoagulants in advanced stages of development using PubMed and abstracts from thrombosis meetings. Most clinical trial data have demonstrated equal or superior efficacy in venographic endpoints in comparison to low-molecular-weight heparins (LMWH). However, bleeding complications have been reported to occur with oral anticoagulants as frequently as or more frequently than with LMWH. Other potential complications reported include liver enzyme elevation and cardiac irregularities. It remains to be established whether newer oral anticoagulants will be better alternatives to the current standard-ofcare in real-life medical clinical practice.

KW - Oral anticoagulants

KW - Prophylaxis

KW - Safety

KW - Venous thromboembolism

UR - http://www.scopus.com/inward/record.url?scp=79960050357&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960050357&partnerID=8YFLogxK

U2 - 10.1160/TH10-10-0653

DO - 10.1160/TH10-10-0653

M3 - Article

C2 - 21544312

AN - SCOPUS:79960050357

VL - 106

SP - 45

EP - 57

JO - Thrombosis and Haemostasis

JF - Thrombosis and Haemostasis

SN - 0340-6245

IS - 1

ER -